{"analyses":[{"ciLowerLimit":"3.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.48","estimateComment":"odds ratio \\>1.0 favours Osimertinib 80 mg","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"5.39","statisticalComment":"adjusted for ethnicity (Asian/non-Asian)","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6"},{"groupId":"OG001","value":"31.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR prior to progression or any further therapy.","groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"OG000","title":"Osimertinib 80mg"},{"description":"Platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (All randomised patients)","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).","title":"Objective Response Rate (ORR) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"% of participants"}